rifampin and Leishmaniasis--Diffuse-Cutaneous

rifampin has been researched along with Leishmaniasis--Diffuse-Cutaneous* in 1 studies

Other Studies

1 other study(ies) available for rifampin and Leishmaniasis--Diffuse-Cutaneous

ArticleYear
Case Report: Diffuse Cutaneous Leishmaniasis Successfully Treated with a Combination of Oral Rifampicin and Fluconazole.
    The American journal of tropical medicine and hygiene, 2023, 08-02, Volume: 109, Issue:2

    Diffuse cutaneous leishmaniasis (DCL) is a rare parasitic infection caused by the Leishmania species. Diffuse cutaneous leishmaniasis commonly presents as non-ulcerating papules and nodules over the face, neck, and arms. A middle-aged female presented with multiple nodular lesions on her face, neck, and chest region. Histopathology of the lesions showed multiple amastigotes, confirming the diagnosis of DCL. She was successfully treated with a combination course of rifampicin and fluconazole. Here, we report the first case of DCL in north India, a non-endemic area for cutaneous leishmaniasis.

    Topics: Female; Fluconazole; Humans; Leishmania; Leishmaniasis, Cutaneous; Leishmaniasis, Diffuse Cutaneous; Middle Aged; Rifampin

2023